Evaluation of Short-to-medium Term Efficacy of Guselkumab and Secukinumab in Overweight and Obese Patients with Moderate to Severe Plaque Psoriasis: A 24-Week Single-center Retrospective Study
Guselkumab and Secukinumab demonstrated good short-to-medium-term efficacy in Chinese patients with moderate to severe plaque psoriasis. In patients with a BMI ≥25 kg/m<sup>2</sup>, Secukinumab demonstrated a faster onset of efficacy, while Guselkumab demonstrated significantly higher efficacy at week 24.
Authors
- Yang Li (ORCID: https://orcid.org/0000-0002-9725-8774)
- Xiuqiu Lin
- Min Ou (ORCID: https://orcid.org/0000-0001-9179-072X)
- Yunling Yan (ORCID: https://orcid.org/0000-0001-9339-7294)
- Xiaohua Wang (ORCID: https://orcid.org/0000-0001-9122-1535)
- Junjie Lin (ORCID: https://orcid.org/0009-0009-7748-9231)
Institutions
- Third Affiliated Hospital of Southern Medical University (CN)
- Shenzhen Chronic Disease Prevention Center (CN)
- Fuzhou Dermatosis Prevention Hospital (CN)
- Huizhou Central People's Hospital (CN)
- Shenzhen Nanshan Center for Chronic Disease Control (CN)
- Southern Medical University (CN)
- Huizhou University (CN)
Publication Details
- Journal
- Indian Journal of Dermatology
- Published
- 2025-08-05
- DOI
- https://doi.org/10.4103/ijd.ijd_663_23
- Citations
- 2
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 1.59